Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 3/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
| ▸ | AOC1 | P19801 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469740 | 0.79 | PRSS1 (0.34) | — | |
| SCHEMBL17469741 | 0.76 | MAPK14 (0.33) | — | |
| SCHEMBL17469730 | 0.76 | TMPRSS2 (0.48) | NQO2ASIC3TMPRSS2FURINAOC1 | |
| SCHEMBL17469657 | 0.68 | TMPRSS2 (0.56) | NQO2ASIC3TMPRSS2FURINAOC1 | |
| SCHEMBL18999199 | 0.65 | TMPRSS2 (0.33) | ASIC3TMPRSS2FURINAOC1SAT1 | |
| SCHEMBL17469669 | 0.65 | TMPRSS2 (0.52) | NQO2ASIC3TMPRSS2FURINAOC1 | |
| SCHEMBL28995725 | 0.65 | NPC1 (0.37) | APP | |
| SCHEMBL18999200 | 0.65 | ASIC3 (0.38) | ASIC3TMPRSS2FURINAOC1SAT1 | |
| SCHEMBL18574217 | 0.65 | ASIC3 (0.71) | NQO2ASIC3APP | |
| SCHEMBL8973401 | 0.64 | ASIC3 (0.58) | ASIC3TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | NQO2 51/4885ASIC3 4763/4885TMPRSS2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.